Drug intelligence / Profile preview

MGX-103

Development stage: Preclinical
Lead developer: Mabgenex
Modality: Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous, Intramuscular

Overview

MGX-103 is a single-domain antibody (sdAb) therapeutic candidate currently in the discovery stage for the treatment of solid tumors. Developed by Mabgenex, the asset leverages the company's expertise in single-domain antibody engineering to create high-affinity biologics. While the specific molecular target of MGX-103 has not been publicly disclosed, the program is part of a broader oncology pipeline aimed at developing next-generation targeted therapies and cancer immunotherapies.

Beyond the preview

Go deeper on MGX-103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MGX-103.

Explore the full profile